Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Roeker LE, Woyach JA, Cheah CY, Coombs CC, et al. Blood 2024;144:1374-1386.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Roeker LE, Woyach JA, Cheah CY, Coombs CC, et al. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood 2024;144:1374-1386.
PMID: 38861666